Sequenom Inc. Message Board

CBMX is also developing a chromosomal microarray analysis (CMA) for genetic prenatal diagnosis and evaluation of stillbirths. Their CMA test would replace karyotyping (a test to examine chromosomes in a sample of cells, which can help identify genetic problems as the cause of a disorder or disease). Both tests detect chromosomal disorders.
The announcement Friday of two studies published in leading journals favors CBMX’s CMA over karyotyping. Their test, a women’s health service option, could complement SQNM’s rather than competing. If SQNM is going to grow into the testing service of choice for pregnant woman, it needs a spectrum of conclusions for the expectant parents. So, CMBX and others should be considered as possible candidates for mergers.

Why don't you read what the company does and what products they have and then you can tell us what you think.....

That's a better idea than you trying to cast doubt on how CBMX will hinder sqnm's success...

Sentiment: Strong Buy